<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367289">
  <stage>Registered</stage>
  <submitdate>20/10/2014</submitdate>
  <approvaldate>4/11/2014</approvaldate>
  <actrnumber>ACTRN12614001161617</actrnumber>
  <trial_identification>
    <studytitle>The role of Intraperitoneal Ropivacaine in Laparoscopic Appendicectomy: A prospective, double blinded randomised control study</studytitle>
    <scientifictitle>The effect of intraperitoneal Ropivacaine on post-laparoscopic pain in appendicectomy patients compared with the effect of intraperitoneal normal saline. </scientifictitle>
    <utrn>U1111-1163-0786 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Appendicitis
</healthcondition>
    <healthcondition>Abdominal pain</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intraperitoneal injection of 0.5ml per kilogram of 0.2% Ropivacaine after the insertion of suprapubic port and another 0.5ml per kilogram of the same solution at the end of laparoscopic appendicectomy.  </interventions>
    <comparator>Intraperitoneal injection of 0.5ml per kilogram of Normal Saline after the insertion of suprapubic port and another 0.5ml per kilogram of the same solution at the end of laparoscopic appendicectomy.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total amount of Intravenous Fentanyl used after operation. Including recovery period and Patient controlled intravenous analgesia used. </outcome>
      <timepoint>1. Immediate post op period (0-4 hours).
2. Up to 16 hours post operation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Verbal response regarding presence or absence of postoperative nausea and vomiting</outcome>
      <timepoint>Up to 16 hours post operation. 
Divided into immediate period (0-4 hours) and from 4-16 hours. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Verbal response regarding presence or absence of postoperative shoulder tip pain. </outcome>
      <timepoint>Up to 16 hours post operation. 
Divided into immediate period (0-4 hours) and from 4-16 hours. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Length of hospital stay. Data collected from patient medical records. </outcome>
      <timepoint>At patient discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients undergoing laparoscopic appendicectomy at Armadale Hospital</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Medical or psychiatric conditions that compromise patients ability to give informed consent 
2. Pregnant or breast feeding
3. Allergies to paracetamol, fentanyl or ropivacaine. 
4. Liver failure
5. Conversion from laparoscopic surgery to open surgery
6. Presence of faecal peritonitis
7. ASA III
8. Iatrogenic perforation
9. Chronic pain syndrome
10. Operative time more than 2 hours. 
11. Drain insertion
12. Weight &gt;100kg
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The patients are recruited during the consenting process for laparoscopic appendicectomy. 

The randomisation and blinding is achieved by the computer software from the Armadale Pharmacy that randomly assigns a blinded solution in the form of 50ml sterile syringes (can have maximum 3 syringes per patient) labelled as number 1-128. These blinded solutions will contain 64 as placebo saline and the other 64 as 0.2% Ropivicaine. The pharmacy will blind the labeling hence blinding both the surgeon and anaesthetist. </concealment>
    <sequence>Computer software from the Armadale Pharmacy that randomly assigns a blinded solution in the form of 50mls sterile syringes (can have maximum 3 syringes per patient) labelled as number 1-128. These blinded solutions will contain 64 as placebo saline and the other 64 as 0.2% Ropivacaine. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Sample size determined by power study approximately 100. For a 50% difference between the post-operative analgesic consumption in the control and treatment group would be of interest. Assuming a one sided significance of 0.05 and a power of 0.8,  a total of 51 patients per group with a total sample size of 102 for a one tailed test and for two tailed test then the recommendation is 128 patients in total. 
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/04/2015</anticipatedstartdate>
    <actualstartdate>6/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/08/2017</actualenddate>
    <samplesize>128</samplesize>
    <actualsamplesize>128</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Armadale Kelmscott Memorial Hospital - Armadale</hospital>
    <postcode>6112 - Armadale</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Armadale and Kelmscott Memorial Hospital</primarysponsorname>
    <primarysponsoraddress>3056 Albany Highway Armadale WA 6112</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the analgesic effect of intraperitoneal injection of a long acting local anaesthetic agent (Ropivacaine) during laparoscopic (keyhole) appendicectomy. 

Trial participants will be randomly divided into two groups. One group will receive intraperitoneal Ropivacaine during laparoscopic appendicectomy while the other will receive normal saline. 

The consumption quantity of total Fentanyl analgesia, the presence of shoulder tip pain and post surgery nausea or vomiting will be recorded up to 16 hours post surgery.
 
The study aims to determine whether the use of Ropivacaine during laparoscopic appendectomy is an useful analgesic adjunct. 

The primary aim of this study will be to determine whether using Ropivacaine will reduce total amount of analgesia used, hence reducing post-operative pain, and its effect on the incidence of post laparoscopic appendicectomy shoulder tip pain and nausea or vomiting. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee South Metropolitan Health</ethicname>
      <ethicaddress>Demountable 3, G Block, Fremantle Hospital
PO Box 480, Fremantle, WA, 6959
</ethicaddress>
      <ethicapprovaldate>29/12/2014</ethicapprovaldate>
      <hrec>14/74</hrec>
      <ethicsubmitdate>10/10/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Yang Yang Huang</name>
      <address>Department of General Surgery
Armadale Health Service
3056 Albany Hwy, Armadale WA 6112

</address>
      <phone>+61040299063</phone>
      <fax />
      <email>yang.huang@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yang Yang Huang</name>
      <address>Department of General Surgery
Armadale Health Service
3056 Albany Hwy, Armadale WA 6112

</address>
      <phone>+61 8 9391 2000</phone>
      <fax />
      <email>yang.huang@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yang Yang Huang</name>
      <address>Department of General Surgery
Armadale Health Service
3056 Albany Hwy, Armadale WA 6112

</address>
      <phone>+61 8 9391 2000</phone>
      <fax />
      <email>yang.huang@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yang Yang Huang</name>
      <address>Department of General Surgery
Armadale Health Service
3056 Albany Hwy, Armadale WA 6112

</address>
      <phone>+61 8 9391 2200</phone>
      <fax>+61 8 9391 2202</fax>
      <email>yang.huang@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>